TNFRSF17 and AL amyloidosis: Additionally, data concerning LCAR-B38M has fueled the development of the anti-BCMA CAR T therapy JNJ-68284528 (Janssen/Johnson & Johnson, Beerse, Belgium) that is currently being evaluated in a phase 1b/2 clinical trial (NCT03548207) for the treatment of patients with relapsed/refractory multiple myeloma [50].